{"id":"NCT03215758","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma","officialTitle":"A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-01","primaryCompletion":"2019-07-02","completion":"2019-07-30","firstPosted":"2017-07-12","resultsPosted":"2020-02-12","lastUpdate":"2021-10-07"},"enrollment":675,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"QAW039","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"QAW039","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A randomized, multicenter, double-blind, placebo- controlled parallel-group study to determine the efficacy and safety of QAW039, compared with placebo, when added to standard-of-care (SoC) asthma therapy in adult and adolescent (≥ 12 years) patients with uncontrolled asthma with respect to change from baseline in forced expiratory volume in 1 second (FEV1) at the end of 12 weeks of treatment.","primaryOutcome":{"measure":"Change From Baseline in Pre-dose FEV1 at Week 12","timeFrame":"Week 12","effectByArm":[{"arm":"QAW039","deltaMin":0.112,"sd":0.0167},{"arm":"Placebo","deltaMin":0.071,"sd":0.0169}],"pValues":[{"comp":"OG000 vs OG001","p":"0.088"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":110,"countries":["United States","Argentina","Germany","Hungary","Mexico","Philippines","Saudi Arabia","Slovakia","South Africa","Turkey (Türkiye)"]},"refs":{"pmids":[],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=593"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":339},"commonTop":["Asthma","Nasopharyngitis","Bronchitis","Rhinitis allergic","Upper respiratory tract infection"]}}